Ford Worthy
Partner @ Pappas Ventures
Durham, United States
Ford Worthy is a Series A investor at Pappas Ventures in Durham focused on Therapeutics and Biotechnology. Ford Worthy joined Pappas Capital as Partner and Senior Advisor in 2019.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ford Worthy invests in
Stages Ford Worthy invests in
Countries Ford Worthy invests in
Investment Focus
Industry
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lumena Pharmaceuticals
|
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to beminimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults. | $45M / Series B / Mar 11, 2014 | |
|
Lumena Pharmaceuticals
|
Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to beminimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults. | $23M / Series A / May 08, 2013 |
Co-Investors
About Pappas Ventures
Pappas Ventures provides investment in the life sciences sector.
Pappas Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Eric W. Linsley
Partner
|
|||
|
Ford Worthy
Partner
|
|||
Franz Humer
Venture partner and Senior editor
|
|||
Mike Grey
Venture Partner
|
|||
Artthur M. Pappas
Founder, CEO & Managing General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ford Worthy invest in?
Ford Worthy invests primarily in Therapeutics, Biotechnology and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ford Worthy last invest?
The most recent investment recorded for Ford Worthy closed in Mar 2014. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
